Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 5/20 | 0.49 |
| ▸ | HINT1 | P49773 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 2/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | TK1 | P04183 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28286364 | 0.87 | ADORA3 (0.49) | PNPHINT1XDHADORA3HPGD | |
| SCHEMBL28076051 | 0.87 | TK1 (0.38) | HINT1HPGDTK1 | |
| SCHEMBL9232430 | 0.86 | ADORA3 (0.46) | PNPHINT1XDHADORA3HPGD | |
| SCHEMBL16163345 | 0.86 | ADORA3 (0.44) | PNPHINT1ADORA3HPGDTK1 | |
| SCHEMBL5611914 | 0.85 | ADORA3 (0.46) | PNPHINT1ADORA3HPGDTK1 | |
| SCHEMBL6826568 | 0.85 | ADORA3 (0.45) | PNPHINT1ADORA3HPGDTK1 | |
| SCHEMBL28319357 | 0.84 | ADORA3 (0.44) | PNPHINT1ADORA3HPGDTK1 | |
| SCHEMBL439017 | 0.84 | PNP (0.48) | PNPHINT1XDHADORA3HPGD | |
| SCHEMBL9116042 | 0.83 | ADORA3 (0.43) | PNPHINT1ADORA3HPGDTK1 | |
| SCHEMBL1135612 | 0.83 | TK1 (0.44) | PNPHINT1ADORA3HPGDTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12203072-B2 | Chemically modified single-stranded rna-editing oligonucleotides | PROQR THERAPEUTICS II B.V. (NL) | 2025-01-21 | — | — | US | claimed |
| US-20240271131-A1 | CHEMICALLY MODIFIED SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDES | PROQR THERAPEUTICS II B.V. (NL) | 2024-08-15 | — | — | US | claimed |
| EP-4728071-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE | ProQR Therapeutics II B.V. (NL) | 2026-04-22 | — | — | EP | disclosed |
| US-12398393-B2 | RNA-editing oligonucleotides for the treatment of usher syndrome | PROQR THERAPEUTICS II B.V. (NL) | 2025-08-26 | — | — | US | disclosed |
| US-12391929-B2 | Polymerase-nucleotide conjugates for sequencing by trapping | ELEMENT BIOSCIENCES, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250236903-A1 | COMPOSITIONS AND METHODS FOR PAIRWISE SEQUENCING | ELEMENT BIOSCIENCES, INC. | 2025-07-24 | — | — | US | disclosed |
| US-20250223593-A1 | CHEMICALLY MODIFIED SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDES | PROQR THERAPEUTICS II B.V. (NL) | 2025-07-10 | — | — | US | disclosed |
| US-20250172547-A1 | MULTIVALENT BINDING COMPOSITION FOR NUCLEIC ACID ANALYSIS | ELEMENT BIOSCIENCES, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250154504-A1 | GUIDE OLIGONUCLEOTIDES FOR NUCLEIC ACID EDITING IN THE TREATMENT OF HYPERCHOLESTEROLEMIA | PROQR THERAPEUTICS II B.V. (NL) | 2025-05-15 | — | — | US | disclosed |
| US-12241891-B2 | Multivalent binding composition for nucleic acid analysis | ELEMENT BIOSCIENCES, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-4508060-A1 | RNA MOLECULE CONTAINING MODIFIED CAP ANALOGS AT THE 5 ' END, USE OF RNA MOLECULE IN IN VITRO PROTEIN OR PEPTIDE SYNTHESIS, RNA MOLECULE FOR USE IN MEDICINE, AND USE OF MODIFIED CAP ANALOGS FOR RNA CAPPING | Uniwersytet Warszawski (PL) | 2025-02-19 | — | — | EP | disclosed |
| US-20170307614-A1 | Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same | UNIV YALE (US) | 2017-10-26 | — | — | US | disclosed |
| US-9632089-B2 | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same | YALE UNIVERSITY (US) | 2017-04-25 | — | — | US | disclosed |
| US-20170067874-A1 | Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-09 | — | — | US | disclosed |
| US-9500653-B2 | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same | YALE UNIVERSITY (US) | 2016-11-22 | — | — | US | disclosed |
| US-20140302523-A1 | Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same | YALE UNIVERSITY (US) | 2014-10-09 | — | — | US | disclosed |
| CN-103502275-A | Small molecule hydrophobic labelling of fusion proteins and resulting degradation thereof | UNIV YALE | 2014-01-08 | — | — | CN | disclosed |
| EP-2649099-A2 | SMALL-MOLECULE HYDROPHOBIC TAGGING OF FUSION PROTEINS AND INDUCED DEGRADATION OF SAME | Yale University (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012078559-A2 | SMALL-MOLECULE HYDROPHOBIC TAGGING OF FUSION PROTEINS AND INDUCED DEGRADATION OF SAME | YALE UNIVERSITY (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2001085221-A2 | ASSESSING LEVELS OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE IN VIVO | DUKE UNIVERSITY (US) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154504-A1 | GUIDE OLIGONUCLEOTIDES FOR NUCLEIC ACID EDITING IN THE TREATMENT OF HYPERCHOLESTEROLEMIA | PCSK9, LDLR, PCSK7 | PNP 990/4885HINT1 2038/4885XDH 2480/4885 |
| US-20170067874-A1 | Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same | HSP90B1, LAMP2, PSMG3 | PNP 4668/4885HINT1 1789/4885XDH 4792/4885 |
| US-20170307614-A1 | Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same | HSP90B1, LAMP2, PSMG3 | PNP 4701/4885HINT1 1745/4885XDH 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.